Unknown

Dataset Information

0

PDE3-inhibitor enoximone prevented mechanical ventilation in patients with SARS-CoV-2 pneumonia.


ABSTRACT:

Background

Standard care in severe SARS-CoV-2 pneumonia complicated by severe dyspnea and respiratory failure, consists of symptom reduction, ultimately supported by mechanical ventilation. Patients with severe SARS-CoV-2, a prominent feature of COVID-19, show several similar symptoms to Critical Asthma Syndrome (CAS) patients, such as pulmonary edema, mucus plugging of distal airways, decreased tissue oxygenation, (emergent) exhaustion due to severe dyspnea and respiratory failure. Prior application of elective phosphodiesterase (PDE)3-inhibitors milrinone and enoximone in patients with CAS yielded rapid symptomatic relief and reverted the need for mechanical ventilation, due to their bronchodilator and anti-inflammatory properties. Based on these observations, we hypothesized that enoximone may be beneficial in the treatment of patients with severe SARS-CoV-2 pneumonia and prominent CAS-features.

Methods

In this case report enoximone was administered to four consecutive patients (1?M; 3?F; 46-70?y) with emergent respiratory failure due to SARS-CoV-2 pneumonia. Clinical outcome was compared with three controls who received standard care only.

Results

After an intravenous bolus of enoximone 20?mg followed by 10?mg/h via perfusor, a rapid symptomatic relief was observed: two out of four patients recovered within a few hours, the other two (with comorbid COPD GOLD II/III) responded within 24-36?h. Compared to the controls, in the enoximone-treated patients respiratory failure and further COVID-19-related deterioration was reverted and mechanical ventilation was prevented, leading to reduced hospital/ICU time.

Discussion

Our preliminary observations suggest that early intervention with the selective PDE3-inhibitor enoximone may help to revert respiratory failure as well as avert mechanical ventilation, and reduces ICU/hospital time in patients with severe SARS-CoV-2 pneumonia. Our findings warrant further research on the therapeutic potential of PDE3-inhibition, alone or in combination with other anti-COVID-19 strategies.

SUBMITTER: Beute J 

PROVIDER: S-EPMC7876671 | BioStudies | 2021-01-01

REPOSITORIES: biostudies

Similar Datasets

2021-01-01 | S-EPMC7934807 | BioStudies
2021-01-01 | S-EPMC7844782 | BioStudies
2020-01-01 | S-EPMC7475952 | BioStudies
2020-01-01 | S-EPMC7498473 | BioStudies
2020-01-01 | S-EPMC7753335 | BioStudies
2020-01-01 | S-EPMC7817886 | BioStudies
2020-01-01 | S-EPMC7388119 | BioStudies
2020-01-01 | S-EPMC7450252 | BioStudies
2005-01-01 | S-EPMC7095783 | BioStudies
2020-01-01 | S-EPMC7260472 | BioStudies